105AD7 vaccine data

IMCL presented data from a Phase I trial showing that 13 patients with advanced colorectal cancer who were immunized with intramuscular doses of 100 µg or 200 µg of 105AD7 had longer median survival than unimmunized patients. Median survival following diagnosis of advanced disease in immunized patients was 12 months, compared with 3 months in unimmunized patients (p<0.001). Patients were followed for up to two years. No patient demonstrated disease regression, though three patients in the treatment group have stable disease. No toxicity related to immunization was seen in the U.K. trial.

The untreated patients weren't enrolled in this trial, but in a Phase III study of an oral chemotherapeutic that used the same entry criteria as the IMCL trial. Median survival of the control group was less than historical data, but the investigators said they were concurrently recruited, had identical entry criteria, were well matched and randomized in their trial. ...